Titre:
  • Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
Auteur:Blanc, Jeremy; Carnot, Aurélien; Barthélémy, Philippe; Casert, Vinciane; Sautois, Brieuc; Van den Brande, Jan; Vanhaudenarde, Vincent; Staudacher, Lionel; Seront, Emmanuel; Debien, Veronique; Ameye, Lieveke; Kotecki, Nuria; Rothé, Françoise; Rorive, Sandrine; Fantoni, Jean Christophe; Tricard, Thibault; Roumeguère, Thierry; Awada, Ahmad; Martinez Chanza, Nieves
Informations sur la publication:Journal for ImmunoTherapy of Cancer, 13, 5
Statut de publication:Publié, 2025-05-01
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Bladder Cancer
Genitourinary Cancer
Immune Checkpoint Inhibitor
Neoadjuvant
MeSH keywords:Humans
Urinary Bladder Neoplasms -- drug therapy -- pathology -- mortality
Male
Female
Aged
Neoadjuvant Therapy -- methods
Antibodies, Monoclonal, Humanized -- therapeutic use -- pharmacology -- administration & dosage
Middle Aged
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use -- adverse effects
Cisplatin -- administration & dosage
Gemcitabine
Aged, 80 and over
Neoplasm Invasiveness
Deoxycytidine -- analogs & derivatives -- administration & dosage
Langue:Anglais
Identificateurs:urn:issn:2051-1426
info:doi/10.1136/jitc-2025-012045
info:pii/jitc-2025-012045
info:pmid/40413024
PMC12104948